DCF Advisers LLC Purchases 67,156 Shares of Evotec SE (NASDAQ:EVO)

DCF Advisers LLC increased its position in shares of Evotec SE (NASDAQ:EVO) by 140.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 114,953 shares of the company’s stock after purchasing an additional 67,156 shares during the quarter. DCF Advisers LLC’s holdings in Evotec were worth $552,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Quadrant Capital Group LLC purchased a new stake in shares of Evotec during the 4th quarter valued at $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in Evotec in the second quarter worth about $87,000. Cetera Advisors LLC purchased a new position in Evotec in the first quarter valued at about $188,000. Optiver Holding B.V. grew its position in shares of Evotec by 643.1% during the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after acquiring an additional 69,936 shares during the period. Finally, Mubadala Investment Co PJSC purchased a new stake in shares of Evotec during the 4th quarter worth approximately $53,931,000. 5.81% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on EVO. Deutsche Bank Aktiengesellschaft lowered Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. Morgan Stanley downgraded shares of Evotec from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $15.00 to $6.00 in a research note on Monday, July 29th. Finally, HC Wainwright dropped their price target on shares of Evotec from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th.

Evotec Price Performance

Shares of EVO opened at $3.64 on Friday. Evotec SE has a 1-year low of $2.85 and a 1-year high of $12.00. The company has a quick ratio of 1.73, a current ratio of 1.83 and a debt-to-equity ratio of 0.42. The firm’s 50 day simple moving average is $3.85 and its 200 day simple moving average is $5.19.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.